List view / Grid view
4 May 2017 | By Niamh Marriott, Junior Editor
Abivax’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients...
13 April 2015 | By Victoria White
ABIVAX, a biotechnology company developing first-in-class anti-viral drugs and vaccines, has announced publication of the mechanism of action of ABX464...
13 November 2014 | By ABIVAX
ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba...
4 November 2014 | By ABIVAX
ABIVAX has appointed Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively...
